2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100050
    4-Hydroxymidazolam 59468-85-8 98%
    4-Hydroxymidazolam is a major metabolite of Midazolam. Midazolam is a potent benzodiazepine with anxiolytic properties.
    4-Hydroxymidazolam
  • HY-100057
    BMY 28674 125481-61-0 98%
    BMY 28674 (6-Hydroxybuspirone) is the active metabolite of the anxiolytic buspirone (HY-B1115A) and is metabolized by CYP3A4.4. BMY 28674 binds to the serotonin (5-HT) receptor subtype 5-HT1A in the rat hippocampus and dorsal raphe (EC50s are 4 and 1 μM, respectively) and is an antagonist of dopamine D2, D3, and D4 receptors (IC50s are 3.1, 4.9, and 0.85 μM, respectively). BMY 28674 also inhibits organic cation transporter 1 (OCT1), OCT2, and OCT3 expressing human transporters in S2 proximal tubule cells in a concentration-dependent manner.
    BMY 28674
  • HY-100124
    Bamaluzole 87034-87-5 98%
    Bamaluzole is a GABA receptor agonist extracted from patent WO 2012064642 A1.
    Bamaluzole
  • HY-100154
    Darenzepine 84629-61-8 98%
    Darenzepine is a muscarinic receptor inhibitor extracted from patent US 20170095465 A1.
    Darenzepine
  • HY-100159
    Ipenoxazone 104454-71-9 98%
    Ipenoxazone is a potent and centrally acting muscle relaxant.
    Ipenoxazone
  • HY-100161
    CI-943 89239-35-0 98%
    CI-943 is a potential antipsychotic agent.
    CI-943
  • HY-100174
    W-2429 37795-69-0 98%
    W-2429 (NSC294836) is considerably more effective than acetylsalicylic acid in inhibiting carrageenan-induced edema and in reducing brewer's yeast-induced fever in rats.
    W-2429
  • HY-100178
    CX-157 205187-53-7 98%
    CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC50 of 19.3 ng/mL.
    CX-157
  • HY-10019S
    Varenicline-d4 2183239-01-0 98%
    Varenicline-d4 is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment.
    Varenicline-d4
  • HY-100206
    5α-Androstane-3β,5,6β-triol 4725-51-3 99.74%
    5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo.
    5α-Androstane-3β,5,6β-triol
  • HY-10020S
    Varenicline-15N3 hydrochloride 1244134-80-2 98%
    Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the 15N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline-15N3 hydrochloride
  • HY-100248
    Sarmazenil 78771-13-8 98%
    Sarmazenil is a benzodiazepine receptor antagonist.
    Sarmazenil
  • HY-100255
    Tiodazosin 66969-81-1 98%
    Tiodazosin is a potent competitive postsynaptic alpha adrenergic receptor antagonist.
    Tiodazosin
  • HY-100257
    Sodium Channel inhibitor 2 653573-60-5 98%
    Sodium Channel inhibitor 2 is a sodium channel blocker extracted from patent WO 2004011439 A2, compound 3c.
    Sodium Channel inhibitor 2
  • HY-100263
    Metofenazate 388-51-2 98%
    Metofenazate is a selective calmodulin inhibitor.
    Metofenazate
  • HY-100264
    Uldazepam 28546-58-9 98%
    Uldazepam is a benzodiazepine derivative and has the potential for anxiety syndrome treatment.
    Uldazepam
  • HY-100265
    Cinperene 14796-24-8 98%
    Cinperene is an atropine-like agent which can block pilocarpine-induced lacrimation and salivation.
    Cinperene
  • HY-100291
    SX-3228 156364-04-4 98%
    SX-3228 is a selective benzodiazepine1 (BZ1) receptor agonist with an IC50 of 17 nM.
    SX-3228
  • HY-100294
    Ruzadolane 115762-17-9 98%
    Ruzadolane (UP 26-91) is a non-narcotic, centrally-acting analgesic agent.
    Ruzadolane
  • HY-100310
    N-type calcium channel blocker-1 241499-17-2 98%
    N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block N-type calcium channels with an IC50 of 0.7 μM in the IMR32 assay.
    N-type calcium channel blocker-1
Cat. No. Product Name / Synonyms Application Reactivity